Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Janna Williams"'
Autor:
Kendall Kling, Rebecca Osborn, Adil Menon, Janna Williams, Ryan Cardew, Omar Al-Heeti, Phillip Santoiemma, Michael Angarone, Samuel Gatesy, Travis Kochan, Teresa Zembower, Karen Krueger, Egon A. Ozer, Chao Qi
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 33, Iss , Pp 100397- (2023)
Mycobacterium xenopi is a slow growing non-tuberculous mycobacterium (NTM) isolated from water systems and has been associated with pseudo-outbreaks and pulmonary infections in humans. We observed a cluster of six respiratory cultures positive for M.
Externí odkaz:
https://doaj.org/article/e411352e07e141569941ecdfd5fe662c
Autor:
Adovich S. Rivera, Omar Al-Heeti, Lucia C. Petito, Mathew J. Feinstein, Chad J. Achenbach, Janna Williams, Babafemi Taiwo
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)
Key points Question Is statin use prior to hospital admission for COVID-19 associated with reducing severe inpatient outcomes? Findings In this observational study using electronic health records from a multi-hospital health system in Chicago, we use
Externí odkaz:
https://doaj.org/article/9fcbd9b911734c4f8870cd82a9f1292a
Autor:
Ajay Bhasin, Karen Marie Krueger, Janna Williams, Reeti Gulati, Nathan Sisler, Shannon Galvin
Publikováno v:
Internal and Emergency Medicine. 18:185-191
A diabetic foot ulcer is present in approximately 2.4% of hospitalized patients. Care for diabetic foot ulcers is highly variable. We sought to describe care practice patterns and risk factors for poor outcomes for patients hospitalized with a diabet
Publikováno v:
Cardiovascular toxicology. 17(3)
In the setting of flecainide toxicity, supraventricular tachycardia can manifest as a bizarre right or left bundle branch block, sometimes with a northwest axis, and can easily be mistaken for ventricular tachycardia leading to inappropriate therapy.
Publikováno v:
Journal of the American College of Cardiology. 67:1037
Flecainide is a Vaughan-Williams Class 1c antiarrhythmic drug indicated for use in pharmacologic cardioversion and maintenance of sinus rhythm in atrial fibrillation and other supraventricular tachycardias in patients without structural heart disease